#BEGIN_DRUGCARD DB06771

# AHFS_Codes:
52:04.04

# ATC_Codes:
S01AE08

# Absorption:
Although ocular surface concentrations are high, average systemic concentrtions after three-times daily dosing was less than 0.5 ng/mL. This indicates that besifloxacin is not appreciably absorbed into the systemic and has a very low risk of systemic side effects.

# Biotransformation:
No appreciable metabolism

# Brand_Mixtures:
Not Available

# Brand_Names:
Besivance

# CAS_Registry_Number:
141388-76-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C19H21ClFN3O3

# Chemical_IUPAC_Name:
7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-14 10:21:02 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

# Dosage_Forms:
Suspension / drops	Ophthalmic

# Drug_Category:
Antibiotic, Ophthalmic
Quinolones

# Drug_Interactions:
Not Available

# Drug_Reference:
19492955	Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW: Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116.
22729919	O'Brien TP: Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not soluble in water

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Besifloxacin

# HET_ID:
Not Available

# Half_Life:
The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.

# InChI_Identifier:
InChI=1S/C19H21ClFN3O3/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23/h7,9-11H,1-6,8,22H2,(H,26,27)/t10-/m1/s1

# InChI_Key:
InChIKey=QFFGVLORLPOAEC-SNVBAGLBSA-N

# Indication:
Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D08872

# LIMS_Drug_ID:
6777

# Mechanism_Of_Action:
Besifloxacin is a bactericidal fluroquinolone-type antibiotic that inhibits bacterial enzymes, DNA gyrase and topoisomerase IV. By inhibiting DNA gyrase, DNA replication, transcription, and repair is impaired. By inhibiting topoisomerase IV, decatenation during cell devision is impaired. Inhibiting these two targets also slows down development of resistance.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
393.84

# Molecular_Weight_Mono:
393.125547465

# Organisms_Affected:
Gram negative and gram positive bacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Besifloxacin tear concentrations were higher than MIC90 (minimum inhibitory concentration) values for common bacterial pathogens and sustained for 24 hours or longer. Mean residence time in the conjunctiva was 4.7 hours.

# Predicted_LogP_Hydrophobicity:
0.7

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.43e-01 g/l

# Primary_Accession_No:
DB06771

# Protein_Binding:
None

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/besivance-drug.htm

# Salts:
Besifloxacin hydrochloride

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H]1CCCCN(C1)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1Cl)C(O)=O

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
BOL-303224-A
SS734

# Synthesis_Reference:
Not Available

# Toxicity:
LD50, rat: >2000 mg/kg. The most common adverse reaction reported in 2% of patients treated with besifloxacin was conjunctival redness.

# Update_Date:
2013-05-24 14:35:06 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Besifloxacin

# pKa_Isoelectric_Point:
6.0-7.0

# Drug_Target_1_Cellular_Location:
Bacterial cell membrane
peripheral membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
20030427	Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L42023

# Drug_Target_1_GenBank_ID_Protein:
1574370

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
parC

# Drug_Target_1_Gene_Sequence:
>2244 bp
ATGACAAATATCAACTATGAAGGCATTGAGCAAATGCCTCTACGCACCTTCACTGAAAAG
GCTTATCTCAACTATTCTATGTATGTCATCATGGATCGTGCGTTGCCTTTTATCGGTGAT
GGTTTAAAACCCGTTCAACGTCGTATTGTATATGCGATGTCTGAACTTGGCTTAAATGCC
ACGGCAAAATACAAAAAATCTGCTCGTACCGTCGGTGATGTACTCGGTAAATTCCATCCA
CATGGTGACAGTGCTTGTTATGAAGCTATGGTGTTAATGGCACAACCCTTCTCTTATCGT
TATCCACTTGTAGATGGTCAAGGTAACTGGGGGGCACCAGATGATCCAAAATCCTTCGCA
GCCATGCGTTATACGGAATCTCGCCTATCTAAAATCTCTGAAATCTTGTTGAATGAACTC
GGACAAGGAACAGTAGATTATCAACCAAACTTTGATGGAACCTTGGCTGAACCACAATAT
TTACCTGCTCGTTTACCGCATATTTTATTGAACGGCACAACAGGTATTGCGGTGGGGATG
GCCACAGATATTCCACCACACAATATTAACGAAATTGCTGATGCGGCAGTAATGTTGCTA
GATAATCCTAAAGCGGGATTAGATGATGTACTTGAAATTGTTCAAGGCCCAGATTTTCCA
ACAGAAGCGGAAATTATTTCGCCAAAATCAGAAATTCGTAAAATTTATGAGCAAGGTCGT
GGCTCAATAAAAATGCGTGCAACTTGGAAAAAAGAAGACGGTGAAATTATTATTTCAGCG
CTTCCACATCAATCTTCGCCATCCAAAGTCATTGCACAAATAGCCGAACAAATGACGGCA
AAAAAACTGCCAATGCTAGAAGATATTCGAGATGAAGCCGATCACGAAAATCCAATTCGC
ATTGTGCTAGTTCCTCGCTCAAATCGCGTCGATACTGATGCCTTAATGGCACATTTATTT
GCGACCACAGATCTTGAAAAAAGCTACCGTGTAAATATGAATATGATCGGGCTTGATCAT
AAACCAGCGGTAAAAGGCTTATTAGAAATCTTAAATGAATGGCTTGACTTCCGTCGCACA
ACGGTCACTCGTCGCCTTCAATATCGCCTAGATAAAGTGCTCTCTCGCTTGCATATTTTA
GAAGGCTTGATGATAGCCTTTTTAAATATTGATGAAGTTATCGAAATTATACGCCACGAA
GATGATCCAAAAGCAGAGCTTATGGCACGCTTTAATTTAAGCGATGAACAAGCCGATGCC
ATTTTAAATTTACGCTTACGTCATTTAGCGAAATTAGAAGAAAACCAACTCAAAGCAGAA
CAAGATGAACTTGAAAAAGAGCGGTTAAATTTAGAAGCAATTTTAGGATCAGAACGCCGT
TTGAATACGCTTATCAAAAAAGAAATTCAAGAAGATGCGAAAAAATATGCCAATCCACGT
ATGTCTCAACTGGTCGAACGTGAAGAAGCCAAAATGATCTCTGAAAGTGATATGACACCA
GCAGAACCAGTTACTGTCATCTTATCAGAAATGGGCTGGGTACGTTGTGCAAAAGGACAC
GATATTGATCCTAAATCATTAAGCTACAAAGCTGGTGATAGCTATCTAGCTCACGCTTGT
GGCAAAAGTAATCAAGCCGTTGTATTCATTGATAGCACGGGGCGGAGTTATGCACTCGAT
CCGCTTTCCTTGCCTTCCGCTCGCTCCCAAGGCGAACCACTTACAGGTAAACTCAATTTA
CCCACTGGTGCGACCATTGAATATGTTGTAATGGCCAGCGAACAGCAAGAATTATTGATG
GCTTCTGATGCAGGATATGGTTTTATTTGTAAATTTGAAGATTTAATTGCACGTAACAAG
GCTGGAAAAGCCTTGATTTCTTTACCAGAAAATGCCAAAGTGTTGAAGCCTAAAACATTG
ATAAATTCTACCGCACTTGTTGTCGCAATCACATCAGCAGGCAGAATGTTGATTTTTCCA
GCACAGGATTTACCGGTATTATCAAAAGGTAAAGGCAATAAAATGATCACTATTCCCGCA
GCGAATGCAAAAGATCGTAGCGAACTATTGACAAAATTATTGCTTATTTCAGATCAAGCA
AGTCTTGAATTTTATTCTGGAAAACGAAAAATTGTATTAAAACCAGAAGATCTGCAAAAG
TTCCGCGCAGAACGAGGCAGAAAAGGTTCGACATTACCACGTGGATTACATACCAATCTT
GAAATTATGGTAATCGAGCCGTAA

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
477

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
83368

# Drug_Target_1_Name:
DNA topoisomerase 4 subunit A

# Drug_Target_1_Number_of_Residues:
747

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_1_Protein_Sequence:
>DNA topoisomerase 4 subunit A
MTNINYEGIEQMPLRTFTEKAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMSELGLNA
TAKYKKSARTVGDVLGKFHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSFA
AMRYTESRLSKISEILLNELGQGTVDYQPNFDGTLAEPQYLPARLPHILLNGTTGIAVGM
ATDIPPHNINEIADAAVMLLDNPKAGLDDVLEIVQGPDFPTEAEIISPKSEIRKIYEQGR
GSIKMRATWKKEDGEIIISALPHQSSPSKVIAQIAEQMTAKKLPMLEDIRDEADHENPIR
IVLVPRSNRVDTDALMAHLFATTDLEKSYRVNMNMIGLDHKPAVKGLLEILNEWLDFRRT
TVTRRLQYRLDKVLSRLHILEGLMIAFLNIDEVIEIIRHEDDPKAELMARFNLSDEQADA
ILNLRLRHLAKLEENQLKAEQDELEKERLNLEAILGSERRLNTLIKKEIQEDAKKYANPR
MSQLVEREEAKMISESDMTPAEPVTVILSEMGWVRCAKGHDIDPKSLSYKAGDSYLAHAC
GKSNQAVVFIDSTGRSYALDPLSLPSARSQGEPLTGKLNLPTGATIEYVVMASEQQELLM
ASDAGYGFICKFEDLIARNKAGKALISLPENAKVLKPKTLINSTALVVAITSAGRMLIFP
AQDLPVLSKGKGNKMITIPAANAKDRSELLTKLLLISDQASLEFYSGKRKIVLKPEDLQK
FRAERGRKGSTLPRGLHTNLEIMVIEP

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Topoisomerase IV is essential for chromosome segregation. It has relaxation of supercoiled DNA activity. Performs the decatenation events required during the replication of a circular DNA molecule

# Drug_Target_1_SwissProt_ID:
P43702

# Drug_Target_1_SwissProt_Name:
PARC_HAEIN

# Drug_Target_1_Synonyms:
EC 5.99.1.-
Topoisomerase IV subunit A

# Drug_Target_1_Theoretical_pI:
6.42

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
20030427	Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.

# Drug_Target_2_Essentiality:
Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Z67739

# Drug_Target_2_GenBank_ID_Protein:
1490399

# Drug_Target_2_GeneCard_ID:
parC

# Drug_Target_2_Gene_Name:
parC

# Drug_Target_2_Gene_Sequence:
>1944 bp
GTGTCAAAAAAGGAAATCAATATTAACAATTATAATGATGATGCTATTCAGGTGCTAGAA
GGGTTGGATGCGGTCCGAAAACGTCCGGGGATGTATATTGGATCGACCGATGGCGCTGGT
CTTCATCACCTAGTTTGGGAAATCGTTGATAATGCAGTCGATGAAGCCTTGTCTGGGTTT
GGTGATCGTATTGATGTAACTATCAATAAAGACGGTAGTCTAACGGTTCAAGACCATGGA
CGTGGGATGCCGACAGGTATGCACGCTATGGGAATTCCAACTGTTGAGGTTATCTTTACC
ATTCTTCATGCCGGAGGGAAATTCGGTCAAGGTGGCTATAAGACATCAGGTGGACTTCAC
GGAGTGGGTTCTTCCGTTGTTAACGCCCTTTCTAGCTGGTTAGAAGTTGAAATTACCCGT
GATGGCGCAGTTTACAAGCAACGTTTCGAAAATGGTGGAAAACCTGTCACGACTTTGAAG
AAAATCGGTACAGCACCCAAGTCTAAAACAGGCACCAAAGTTACTTTTATGCCTGACGCG
ACTATATTTTCTACGACAGATTTCAAGTACAATACCATTTCAGAGCGCCTTAATGAATCA
GCCTTTCTCTTGAAAAATGTGACCTTGTCTTTAACGGACAAGCGAACAGATGAAGCGATT
GAGTTCCACTATGAGAATGGAGTACAAGATTTTGTTTCTTATCTCAACGAAGATAAGGAA
ATCTTGACGCCAGTTCTTTACTTTGAAGGGGAAGACAATGGTTTTCAAGTGGAAGTAGCC
CTCCAGTACAATGACGGATTCTCAGATAACATTCTATCCTTTGTCAATAACGTTCGCACC
AAGGACGGTGGAACGCACGAGACAGGACTCAAGTCTGCCATTACCAAGGTCATGAATGAC
TATGCACGTAAAACAGGTCTTCTCAAGGAAAAAGATAAAAACCTTGAAGGTTCAGACTAT
CGTGAGGGACTAGCGGCCGTTCTTTCTATCTTAGTTCCTGAAGAACACTTGCAGTTTGAA
GGACAGACCAAGGATAAACTAGGAAGCCCCCTAGCTCGCCCAGTTGTGGATGGAATAGTG
GCTGATAAGTTGACCTTTTTCCTTATGGAAAATGGGGAATTAGCTTCTAACCTCATCCGC
AAGGCTATCAAGGCCCGTGATGCTCGTGAAGCAGCACGTAAGGCGCGTGATGAGAGCCGA
AATGGGAAGAAAAACAAGAAAGATAAGGGCTTGTTGTCTGGGAAATTGACCCCAGCCCAA
TCTAAGAATCCTGCTAAGAATGAACTCTATCTAGTTGAGGGGGACTCTGCCGGTGGTTCT
GCCAAACAAGGTCGTGACCGCAAGTTCCAGGCTATTCTACCTCTTCGTGGTAAGGTTATC
AATACAGCCAAGGCCAAGATGGCGGATATCCTCAAAAATGAAGAGATCAATACCATGATT
TATACCATTGGTGCGGGTGTTGGAGCAGACTTCTCTATTGAAGATGCCAACTATGATAAG
ATCATTATCATGACCGATGCGGATACCGACGGTGCCCATATCCAGACCTTGCTCTTGACA
TTTTTCTACCGTTACATGCGTCCGCTAGTCGAGGCAGGTCATGTCTATATTGCCCTCCCA
CCTCTTTACAAGATGTCCAAAGGTAAAGGAAAGAAAGAAGAAGTGGCCTACGCTTGGACG
GACGGAGAACTAGAAGAACTCCGTAAACAGTTCGGTAAAGGCGCTACCCTCCAACGATAC
AAAGGACTTGGTGAGATGAATGCGGACCAGCTCTGGGAAACAACCATGAACCCAGAAACA
CGTACCCTCATCCGTGTCACAATTGAAGATTTAGCGCGCGCCGAACGCCGCGTCAATGTT
CTCATGGGAGATAAGGTAGAACCACGCCGTAAATGGATTGAAGATAATGTCAAGTTTACG
CTAGAAGAAGCGACAGTGTTTTAA

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
8763932	Pan XS, Fisher LM: Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996 Jul;178(14):4060-9.
8891124	Munoz R, De La Campa AG: ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7.
8913454	Tankovic J, Perichon B, Duval J, Courvalin P: Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6226

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
93132.2

# Drug_Target_2_Name:
DNA topoisomerase 4 subunit A

# Drug_Target_2_Number_of_Residues:
823

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_2_Protein_Sequence:
>DNA topoisomerase 4 subunit A
MSNIQNMSLEDIMGERFGRYSKYIIQDRALPDIRDGLKPVQRRILYSMNKDSNTFDKSYR
KSAKSVGNIMGNFHPHGDSSIYDAMVRMSQNWKNREILVEMHGNNGSMDGDPPAAMRYTE
ARLSEIAGYLLQDIEKKTVPFAWNFDDTEKEPTVLPAAFPNLLVNGSTGISAGYATDIPP
HNLAEVIDAAVYMIDHPTAKIDKLMEFLPGPDFPTGAIIQGRDEIKKAYETGKGRVVVRS
KTEIEKLKGGKEQIVIIEIPYEINKANLVKKIDDVRVNNKVAGIAEVRDESDRDGLRIAI
ELKKDANTELVLNYLFKYTDLQINYNFNMVAIDNFTPRQVGIVPILSSYIAHRREVILAR
SRFDKEKAEKRLHIVEGLIRVISILDEVIALIRASENKADAKENLKVSYDFTEEQAEAIV
TLQLYRLTNTDVVVLQEEEAELREKIAMLAAIIGDERTMYNLMKKELREVKKKFATPRLS
SLEDTAKAIEIDTASLIAEEDTYVSVTKAGYIKRTSPRSFAASTLEEIGKRDDDRLIFVQ
SAKTTQHLLMFTSLGNVIYRPIHELADIRWKDIGEHLSQTITNFETNEEILYVEVLDQFD
DATTYFAVTRLGQIKRVERKEFTPWRTYRSKSVKYAKLKDDTDQIVAVAPIKLDDVVLVS
QNGYALRFNIEEVPVVGAKAAGVKAMNLKEDDVLQSGFICNTSSFYLLTQRGSLKRVSIE
EILATSRAKRGLQVLRELKNKPHRVFLAGAVAEQGFVGDFFSTEVDVNDQTLLVQSNKGT
IYESRLQDLNLSERTSNGSFISDTISDEEVFDAYLQEVVTEDK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Topoisomerase IV is essential for chromosome segregation. It has relaxation of supercoiled DNA activity. Performs the decatenation events required during the replication of a circular DNA molecule (By similarity)

# Drug_Target_2_SwissProt_ID:
P72525

# Drug_Target_2_SwissProt_Name:
PARC_STRPN

# Drug_Target_2_Synonyms:
Topoisomerase IV subunit A

# Drug_Target_2_Theoretical_pI:
5.35

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasmic

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
20030427	Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L42023

# Drug_Target_3_GenBank_ID_Protein:
1574722

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
gyrA

# Drug_Target_3_Gene_Sequence:
>2643 bp
TTATTCTTCAGAACTGCTTTCTTCCAAAGAATCATCTTCATCTGCATCACAAACACGTTC
TAAACTTACTACGTGTTCATCATCGGCAGTACGAATTAAGCGAACACCTTGCGTGTTACG
CCCTACAATGCTCACTTCGCTTACGCGTGTGCGAACAAGGGTTCCTGCATCAGTGATCAA
CATAATTTGGTCTGTTTCTTCTACTTGAGTTGCGGCAACGACTTTACCATTGCGTTCACT
CACTTTAATCGAAATCACACCTTTTGTATTACGTGATTTAGTTGGGTATTCACTTAATTG
TGTGCGTTTTCCGTAGCCGTTTTGCGTTGCGGTTAAAATTGCCCCTTCACCTTTTGGCAC
AACGAGCGAGACCACTTTATCGATATTTAAGTCTAATGATGCTTCAGCGTTGTCATCAGA
AATATCTTCAATTTCTACCGCACTTTCATCGTCAGAAATATCGTTTGTTAAAGCCAGTTT
GATACCGCGAACACCTGTTGCTAAACGCCCCATCGCACGCACGGCATTTTCAGCAAAACG
CACCACGCGACCTTGTGATGAGAACAACATAATTTCGTTGCTGCCATCAGTAATATCCAC
GCCGATTAATTCATCTTCGTCACGTAAATTCAATGCGATGATACCGTTTGAACGTGGACG
GCTAAATTCGGTTAAGGCGATTTTCTTCACAATACCGCCAGCAGTTGCCATGACTACGAA
TTTATCTTCTTCGTAAGCAGAAACTGGCAAGATTGCAGTAATACGTTCGTTTTCTTGTAA
CGGAAGAATATTCACAATTGGACGACCGCGTGCGCCACGGCTCGCTTGCGGAAGTTGATA
TACTTTCAACCAATATAAACGACCACGGCTAGAGAAGCAGAGGATGGTATCGTGAGTATT
TGCTACCAGTAATTTTTCGATGAAATCTTCTTCTTTCATCTTCGTTGCAGATTTGCCTTT
ACCGCCACGGCGTTGTGCTTCATAGTCAGTCAGTGGTTGGTATTTCACATAACCTTCGTG
AGAAAGCGTCACAACCACGTCTTCTTGTGCGATTAAATCTTCTAAATCAATATCGCCAGA
AGCAGCGGTAATTTCAGTTAAACGATCATCACCAAATTGTGCTTTTACTTCTTCCAATTC
TTCACGAATTACTTCCATTAAACGTTCTGCACTACTTAAAATATGAAGAAGATCCGCAAT
TTTAACTAATAATTCTTCATATTCTTTTATAACTTCTTCAAACGCAATGCCCGTTAAACG
GTGTAAGCGAAGTTCTAGAATTGCGTTTACTTGCGCTGGCGATAAGTAATATTGTTCGCC
TTGAATACCAAGATTTTCTTCTAACTCATCAGGACGAGCAGAAGCATCAAGAAGATTAAT
AATATCGCTATGTAACGTCCAAGAGCGTGAACTGATTGATGTTGCGGCTTCTTCACGGTT
TTTAGAGTTACGAATGATCGCAATCATTTCATCGATATTAGAACGAGCAACCGCTAAACC
TTCCAAAATATGCGTACGTTCACGTGCTTTGCGAAGCTCAAAGATAGAACGACGTGTAAC
CACTTCACGGCGGTGTAAAACAAAGGCTTCAATAATTTCTTTAAGATTAAATAAACGTGG
CTGACCGTGATCCAATGCCACCATATTGATACCAAAGGTCACTTGCATTTGAGTGAGTGA
GTAAAGATGGTTTAATACCACTTCCCCCACTGCATCACGTTTAATATCAATTTCAATACG
GATCCCTTCTTTATTTGAAAGGTCAGTAATATTGCTGATACCTTCGATTTTTTTCTCGCG
AATTAATTCGGCGATTTTCTCGACTAATTTTGCTTTATTTACTTGGTATGGCAATTCAGA
CACGATAATTTGCTCGCGTCCTTTTTCGTTGGTTTCTACCGTTGCACGAGCACGAACATA
CACTTTACCACGACCAGTGCGATAGGCCTCTTCAATCCCTTTACGACCATTAATTAACGC
AGCCGTTGGGAAGTCAGGCCCTGGAATATGTTGCATTAATTCATCAATGGTAATTTCATT
TTTGTCAATATAAGCCAAACAACCATTTAATACTTCGTTTAAGTTGTGAGGGGGAATGTT
AGTTGCCATCCCCACCGCAATACCAGAAGAACCATTTGCTAACAGTGCTGGAATACGAGT
CGGCAATACATCTGGAATCATTAATTCGCCATCATAGTTTGGCGAGAAATTGACGGTTTC
TTTATCCAAATCCGTGAGCAATGCTTGCGTAATTTTTTGCATACGTACTTCGGTATAACG
CATTGCAGCTGGCGCATCACCATCAATTGAACCAAAGTTACCTTGCCCATCAACCAACAT
ATAGCGAAGTGAGAAGGGTTGTGCCATACGAACGATGGTATCGTACACGGCGGAGTCACC
ATGCGGGTGATATTTACCGATTACATCACCCACAACACGCGCTGATTTTACGTATTTTTT
ATTGGCGGTATTGCCTTCGCGATCCATTGAGAATAGTACGCGGCGGTGAACAGGTTTTAA
ACCATCTCGAACGTCAGGTAATGCACGCCCAACGATAACCGACATCGCGTAGTCAAGGTA
GGAAGATTTAAGTTCTTCTTCGATATTGACAGGGGTGATAGATGATTGGATTGAATCCGT
CAT

# Drug_Target_3_General_Function:
Replication, recombination and repair

# Drug_Target_3_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
404

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
97820

# Drug_Target_3_Name:
DNA gyrase subunit A

# Drug_Target_3_Number_of_Residues:
880

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_3_Protein_Sequence:
>DNA gyrase subunit A
MTDSIQSSITPVNIEEELKSSYLDYAMSVIVGRALPDVRDGLKPVHRRVLFSMDREGNTA
NKKYVKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDAPAA
MRYTEVRMQKITQALLTDLDKETVNFSPNYDGELMIPDVLPTRIPALLANGSSGIAVGMA
TNIPPHNLNEVLNGCLAYIDKNEITIDELMQHIPGPDFPTAALINGRKGIEEAYRTGRGK
VYVRARATVETNEKGREQIIVSELPYQVNKAKLVEKIAELIREKKIEGISNITDLSNKEG
IRIEIDIKRDAVGEVVLNHLYSLTQMQVTFGINMVALDHGQPRLFNLKEIIEAFVLHRRE
VVTRRSIFELRKARERTHILEGLAVARSNIDEMIAIIRNSKNREEAATSISSRSWTLHSD
IINLLDASARPDELEENLGIQGEQYYLSPAQVNAILELRLHRLTGIAFEEVIKEYEELLV
KIADLLHILSSAERLMEVIREELEEVKAQFGDDRLTEITAASGDIDLEDLIAQEDVVVTL
SHEGYVKYQPLTDYEAQRRGGKGKSATKMKEEDFIEKLLVANTHDTILCFSSRGRLYWLK
VYQLPQASRGARGRPIVNILPLQENERITAILPVSAYEEDKFVVMATAGGIVKKIALTEF
SRPRSNGIIALNLRDEDELIGVDITDGSNEIMLFSSQGRVVRFAENAVRAMGRLATGVRG
IKLALTNDISDDESAVEIEDISDDNAEASLDLNIDKVVSLVVPKGEGAILTATQNGYGKR
TQLSEYPTKSRNTKGVISIKVSERNGKVVAATQVEETDQIMLITDAGTLVRTRVSEVSIV
GRNTQGVRLIRTADDEHVVSLERVCDADEDDSLEESSSEE

# Drug_Target_3_Reaction:
ATP-dependent breakage, passage and rejoining of double-stranded DNA INHIBITOR Coumermycin A1; GRI22222X; Nalidixic acid; Novobiocin; Ciprofloxacin

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_3_SwissProt_ID:
P43700

# Drug_Target_3_SwissProt_Name:
GYRA_HAEIN

# Drug_Target_3_Synonyms:
EC 5.99.1.3

# Drug_Target_3_Theoretical_pI:
4.85

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
20030427	Carter NJ, Scott LJ: Besifloxacin ophthalmic suspension 0.6%. Drugs. 2010;70(1):83-97. doi: 10.2165/11203820-000000000-00000.

# Drug_Target_4_Essentiality:
Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AE005672

# Drug_Target_4_GenBank_ID_Protein:
14971465

# Drug_Target_4_GeneCard_ID:
gyrA

# Drug_Target_4_Gene_Name:
gyrA

# Drug_Target_4_Gene_Sequence:
>1362 bp
TTGAAAGAAAAACAATTTTGGAATCGTATATTAGAATTTGCACAAGAAAGACTGACTCGA
TCCATGTATGATTTCTATGCTATTCAAGCTGAACTCATCAAGGTAGAGGAAAATGTTGCC
ACTATATTTCTACCTCGCTCTGAAATGGAAATGGTCTGGGAAAAACAACTAAAAGATATT
ATTGTAGTAGCTGGTTTTGAAATTTATGACGCTGAAATAACTCCCCACTATATTTTCACC
AAACCTCAAGATACGACTAGCTCACAAGTTGAAGAAGCTACAAATTTAACTCTTTATAAC
TATAGTCCAAAGTTAGTATCTATTCCTTATTCAGATACGGGATTAAAAGAAAAGTATACC
TTTGATAACTTTATTCAAGGGGATGGAAATGTTTGGGCTGTATCAGCCGCTTTAGCTGTC
TCTGAAGATTTGGCTCTGACCTATAACCCTCTTTTTATCTATGGAGGACCAGGCCTTGGT
AAGACTCACTTATTAAACGCTATTGGAAATGAAATTCTAAAAAATATTCCTAATGCGCGT
GTTAAATATATCCCTGCCGAAAGCTTTATTAATGACTTTCTTGATCACCTAAGACTTGGG
GAAATGGAAAAGTTTAAAAAGACCTATCGTAGTCTTGATCTTTTGTTAATCGATGATATC
CAGTCACTCAGCGGAAAAAAAGTCGCAACTCAGGAAGAATTTTTCAATACCTTTAACGCC
CTTCATGACAAGCAAAAACAGATTGTCCTAACGAGTGATCGTAGTCCAAAACATCTAGAA
GGGCTCGAGGAGAGGCTTGTCACGCGTTTTAGTTGGGGATTGACACAAACTATCACCCCC
CCTGACTTTGAAACACGTATTGCCATTTTACAAAGTAAGACGGAACATTTAGGCTACAAT
TTCCAAAGTGATACTCTAGAATACCTAGCTGGGCAATTTGATTCAAATGTTCGAGATCTT
GAGGGAGCCATCAACGACATCACTTTAATTGCCAGAGTAAAAAAAATCAAGGATATCACT
ATTGATATTGCTGCAGAAGCCATTAGAGCCCGCAAACAAGATGTTAGCCAAATGCTCGTC
ATCCCAATTGATAAAATCCAAACTGAAGTTGGTAACTTTTATGGTGTTAGTATCAAAGAA
ATGAAGGGAAGTAGACGCCTTCAAAATATTGTTTTGGCCCGTCAAGTAGCCATGTATTTA
TCTAGAGAACTAACAGATAATAGTCTTCCAAAAATTGGGAAGGAATTTGGGGGAAAAGAT
CATACCACAGTCATTCATGCCCATGCCAAAATAAAATCTTTGATTGATCAAGACGATAAT
TTACGTTTAGAAATTGAATCAATCAAAAAGAAAATCAAATAA

# Drug_Target_4_General_Function:
Replication, recombination and repair

# Drug_Target_4_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
6224

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
92052.6

# Drug_Target_4_Name:
DNA gyrase subunit A

# Drug_Target_4_Number_of_Residues:
822

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00521	DNA_topoisoIV
PF03989	DNA_gyraseA_C

# Drug_Target_4_Protein_Sequence:
>DNA gyrase subunit A
MQDKNLVNVNLTKEMKASFIDYAMSVIVARALPDVRDGLKPVHRRILYGMNELGVTPDKP
HKKSARITGDVMGKYHPHGDSSIYEAMVRMAQWWSYRYMLVDGHGNFGSMDGDSAAAQRY
TEARMSKIALEMLRDINKNTVDFVDNYDANEREPLVLPARFPNLLVNGATGIAVGMATNI
PPHNLGETIDAVKLVMDNPEVTTKDLMEVLPGPDFPTGALVMGKSGIHKAYETGKGSIVL
RSRTEIETTKTGRERIVVTEFPYMVNKTKVHEHIVRLVQEKRIEGITAVRDESNREGVRF
VIEVKRDASANVILNNLFKMTQMQTNFGFNMLAIQNGIPKILSLRQILDAYIEHQKEVVV
RRTRFDKEKAEARAHILEGLLIALDHIDEVIRIIRASETDAEAQAELMSKFKLSERQSQA
ILDMRLRRLTGLERDKIQSEYDDLLALIADLADILAKPERVSQIIKDELDEVKRKFSDKR
RTELMIGQVLSLEDEDLIEESDVLITLSNRGYIKRLDQDEFTAQKRGGRGVQGTGVKDDD
FVRELVSTSTHDHLLFFTNKGRVYRLKGYEIPEYGRTAKGLPVVNLLKLDEDESIQTVIN
VESDRSDDAYLFFTTRHGIVKRTSVKEFANIRQNGLKALNLKDEDELINVLLAEGDMDII
IGTKFGYAVRFNQSAVRGMSRIATGVKGVNLREGDTVVGASLITDQDEVLIITEKGYGKR
TVATEYPTKGRGGKGMQTAKITEKNGLLAGLMTVQGDEDLMIITDTGVMIRTNLANISQT
GRATMGVKVMRLDQDAQIVTFTTVAVAEKEEVGTENETEGEA

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_4_SwissProt_ID:
P72524

# Drug_Target_4_SwissProt_Name:
GYRA_STRPN

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
6.07

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB06771
